EUCTR2017-004004-22-GB进行中（未招募）1 期
A Multi-Centred, Open Label, Randomised Study Assessing the Cardiovascular Outcomes Following Treatment of White Coat Hypertension with Established Anti-Hypertensive Drugs versus Standard of Care in the Very Elderly - Feasibility Study - HYVET 2: Treatment of white coat HYpertension in the Very Elderly
niversity of Sussex0 个研究点目标入组 100 人开始时间: 2018年1月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients =75 years of age
- •Clinic sitting systolic BP =150mmHg but <200mmHg and diastolic BP <110mmHg
- •Diagnosis of white coat hypertension at baseline if the mean ambulatory day time average systolic BP is <135 mmHg and diastolic BP is <85mmHg (from at least 14 measurements) or for HBPM from BP readings twice a day for at least 5 days (ideally 7 days)at baseline
- •Not taken antihypertensive drug therapy within the last 6 months
- •Capacity to consent
- •Provision of documented informed consent
- •Ability to comply with the protocol and additional study visits & assessments
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •Contraindication to the use of indapamide MR and perindopril in accordance with the summary of product characteristics
- •Regular non-steroidal anti-inflammatory drug (NSAID) use. Regular use being defined by the local GP with consideration to cardiovascular risk and blood pressure
- •Hypertensive emergency
- •Secondary hypertension
- •Postural hypotension (postural drop in systolic BP=20mmHg or postural symptoms at screening)
- •Any stroke or myocardial infarction in the previous 6 months
- •Heart failure requiring treatment with drugs having an antihypertensive effect
- •Previous documented evidence of gout
- •eGFR less than 30ml/min
- •Montreal cognitive assessment score (MoCA) < 22
- •Life expectancy <1year due to malignancy or chronic disease
研究者
相似试验
进行中（未招募）
不适用
HYVET 2: treatment of white coat hypertension in the very elderlyWhite coat hypertensionISRCTN13127656niversity of Sussex100
进行中（未招募）
1 期
A study to assess the pharmacokinetics, safety, and efficacy of two doses of bimekizumab in adolescent study participants with moderate to severe plaque psoriasisModerate to Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2020-001724-34-DECB Biopharma SR40
进行中（未招募）
1 期
A study to assess the pharmacokinetics, safety, and efficacy of two doses of bimekizumab in adolescent study participants with moderate to severe plaque psoriasisModerate to Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2020-001724-34-Outside-EU/EEACB Biopharma SR
进行中（未招募）
1 期
A study to assess the pharmacokinetics, safety, and efficacy of two doses of bimekizumab in adolescent study participants with moderate to severe plaque psoriasisModerate to Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2020-001724-34-PLCB Biopharma SR40
进行中（未招募）
1 期
A study to learn how safe bimekizumab, how well it works and how it moves through the bloodstream in adolescents with moderate to severe plaque psoriasisModerate to Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code: 10071117Term: Plaque psoriasis Class: 10040785CTIS2023-509832-24-00CB Biopharma43